Retrospective analysis studying clinical outcomes in psoriasis patients who switched from a biologic medication to either secukinumab or ixekizumab

AbstractBackground: Psoriasis is a chronic immune-mediated disease characterized by raised, red, scaly patches on the skin. While there is no cure, psoriasis medications are used to reduce inflammation and clear skin lesions. Third-generation biologics such as secukinumab, ixekizumab, and brodalumab bind to cytokine IL-17 preventing it from targeting cells and causing inflammation. Studies show that inhibiting IL-17, can help to clear psoriasis. Being that IL-17 inhibitors are newer biologics approved for psoriasis, it is valuable to assess reasons for switching therapies as well as the impact on patients.Objectives: The objectives of this study were to conduct a retrospective analysis studying the factors that lead to patients with psoriasis changing from a psoriasis-indicated biologic medication to secukinumab or ixekizumab, and to identify patient-reported outcomes as a result of switching biologic therapies.Methods: Data were acquired from the proprietary clinical management application and the pharma...